GSK (LON:GSK) Issues Quarterly Earnings Results

GSK (LON:GSK – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported GBX 10.80 earnings per share (EPS) for the quarter, Digital Look Earnings reports. GSK had a return on equity of 35.78% and a net margin of 17.78%.

GSK Stock Performance

GSK stock opened at GBX 1,994.50 on Tuesday. GSK has a twelve month low of GBX 1,288.61 and a twelve month high of GBX 2,282. The company has a quick ratio of 0.73, a current ratio of 0.79 and a debt-to-equity ratio of 106.74. The company has a market cap of £79.89 billion, a P/E ratio of 14.04, a price-to-earnings-growth ratio of 1.24 and a beta of 0.30. The business’s fifty day moving average is GBX 1,933.21 and its 200-day moving average is GBX 1,989.71.

Get GSK alerts:

Insider Buying and Selling

In related news, insider Jeannie Lee acquired 802 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was acquired at an average cost of GBX 5,069 per share, with a total value of £40,653.38. Also, insider Wendy Becker acquired 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 29th. The stock was bought at an average price of GBX 1,963 per share, with a total value of £78,520. Insiders acquired 7,625 shares of company stock valued at $21,347,004 in the last three months. 0.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

GSK has been the subject of several recent research reports. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a report on Thursday, May 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 1,950 target price on shares of GSK in a research note on Monday. Finally, Citigroup lowered their price target on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of GBX 2,041.43.

Read Our Latest Report on GSK

GSK Company Profile

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

Featured Articles

• Five stocks we like better than GSK
• Middleby Is Betting a Leaner Business Can Unlock More Value
• 3 Value ETFs to Consider as Growth Stocks Lag Behind
• Wintrust: A Quiet Regional Bank Posting Loud Results
• AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.